NSCLC Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Xiuning Le, MD, PhD, discusses results from the ZENITH20 trial, which showed that twice daily poziotinib improved AEs and retained anti-tumour activity in EGFR+ or HER2+ NSCLC.
View More
Seeking to expand the armamentarium of personalized treatment regimens for patients with recurrent, KRAS+, NSCLC, D. Ross Camidge, MD, PhD, et al are conducting the RAMP 202 trial.
View More
Dr Lisberg discusses when to use checkpoint inhibitor therapy for targetable mutations in NSCLC, a recap of his presentation at the 2020 Personalized Therapies in Thoracic Oncology meeting.
View More
Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with…
View More
Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.
View More
David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.
View More
Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.
View More
Martin J. Edelman, MD, discusses how the treatment landscape for advanced NSCLC has evolved in recent years.
View More
Jessica Donington, MD, discusses the role of surgery in managing patients with locally advanced NSCLC.
View More
Stay in the know.
OncNet Newsletter